Compare IDEXX Laboratories, Inc. (IDXX) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Progressive Corp — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Progressive Corp trades at $207 (market cap $123.45B). The key difference: Progressive Corp is far larger — about 2.7× IDEXX Laboratories, Inc.'s market cap, and Progressive Corp pays a 6.55% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PGR | |
|---|---|---|
Market Cap | $46.22B | $123.45B |
Sector | Health | Financials |
52-Week High | $766.68 | $252.68 |
52-Week Low | $526.44 | $190.40 |
Enterprise Value | $47.12B | $131.66B |
Dividend Yield | — | 6.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Progressive (PGR) trades at $207.58, down 2.98% on the day, as technical indicators signal a bearish trend. Fundamentally, the company shows strong revenue growth from $49.6B in 2022 to $87.6B in 2025, with net income margins expanding to 12.85%. Recent Q2 2026 earnings beat estimates at $4.85 per share, though Q1 2026 missed expectations. Analyst consensus remains mixed with a $231.20 price target, representing 11.4% upside potential from current levels.
The stock presents a value opportunity with a P/E of 10.65 below industry averages, supported by robust cash flow generation and expanding profitability. Key risks include competitive pressures in insurance markets and potential margin compression from growth investments. Institutional ownership remains substantial despite recent portfolio adjustments by some funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
